Literature DB >> 17853291

Vision in depressive disorder.

Emanuel Bubl1, Ludger Tebartz Van Elst, Matthias Gondan, Dieter Ebert, Mark W Greenlee.   

Abstract

BACKGROUND: Reduced dopaminergic transmission has been implicated in the pathophysiology of major depression. Furthermore, dopaminergic neurotransmission plays an important role in the physiology of visual contrast sensitivity (CS). To test the hypothesis that altered dopaminergic neurotransmission plays a role in major depression we measured contrast sensitivity in patients with major depression and in healthy control subjects.
METHODS: Twenty-eight patients diagnosed with major depressive disorder were compared to 21 age-matched control subjects on their ability to detect a Gabor target with slightly elevated luminance contrast embedded in seven equi-contrast distracters.
RESULTS: Contrast discrimination thresholds were significantly elevated in unmedicated and medicated patients with major depression compared to control subjects, at all pedestal contrast levels tested.
CONCLUSIONS: Contrast discrimination performance is reduced in depressive patients and might reflect a state of altered dopaminergic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 17853291     DOI: 10.1080/15622970701513756

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  15 in total

1.  Retinal dysfunction of contrast processing in major depression also apparent in cortical activity.

Authors:  Emanuel Bubl; Elena Kern; Dieter Ebert; Andreas Riedel; Ludger Tebartz van Elst; Michael Bach
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-01-08       Impact factor: 5.270

2.  Disturbances of visual motion perception in bipolar disorder.

Authors:  Rebecca A O'Bryan; Colleen A Brenner; William P Hetrick; Brian F O'Donnell
Journal:  Bipolar Disord       Date:  2014-01-02       Impact factor: 6.744

3.  From Molecular to Behavior: Higher Order Occipital Cortex in Major Depressive Disorder.

Authors:  Dong-Yu Liu; Xuan Ju; Yuan Gao; Jin-Fang Han; Zhe Li; Xi-Wen Hu; Zhong-Lin Tan; Georg Northoff; Xue Mei Song
Journal:  Cereb Cortex       Date:  2022-05-14       Impact factor: 4.861

Review 4.  Normalization as a canonical neural computation.

Authors:  Matteo Carandini; David J Heeger
Journal:  Nat Rev Neurosci       Date:  2011-11-23       Impact factor: 34.870

5.  Neuroanatomical substrates underlying contrast sensitivity.

Authors:  Ying Yang; Yajun Wang; Cun Zhang; Jiajia Zhu; Yongqiang Yu
Journal:  Quant Imaging Med Surg       Date:  2019-03

6.  Retinal contrast transfer functions in adults with and without ADHD.

Authors:  Emanuel Bubl; Michael Dörr; Alexandra Philipsen; Dieter Ebert; Michael Bach; Ludger Tebartz van Elst
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

Review 7.  A Possible Link between Anxiety and Schizophrenia and a Possible Role of Anhedonia.

Authors:  Luigi Grillo
Journal:  Schizophr Res Treatment       Date:  2018-01-17

8.  Resting state functional connectivity predictors of treatment response to electroconvulsive therapy in depression.

Authors:  M Moreno-Ortega; J Prudic; S Rowny; G H Patel; A Kangarlu; S Lee; J Grinband; T Palomo; T Perera; M F Glasser; D C Javitt
Journal:  Sci Rep       Date:  2019-03-25       Impact factor: 4.379

9.  Psychological contribution to understanding the nature of dry eye disease: a cross-sectional study of anxiety sensitivity and dry eyes.

Authors:  Marko Toth; Nataša Jokić-Begić
Journal:  Health Psychol Behav Med       Date:  2020-05-28

10.  Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?

Authors:  Michele Fornaro; Fabio Bandini; Luca Cestari; Christian Cordano; Carla Ogliastro; Claudio Albano; Domenico De Berardis; Matteo Martino; Andrea Escelsior; Giulio Rocchi; Pantaleo Fornaro; Concetta De Pasquale
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.